Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 9,926 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single-arm Clear all
Completed No phase listed Observational

Delphinus SoftVue Prospective Case Collection - ARM 2

NCT02977247
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Non-Interventional, Automated Whole Breast Ultrasound
Other · Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Los Angeles, California • Miami Beach, Florida • Savannah, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

NCT03976349
View directory record Official record
Conditions
Parkinson's Disease
Interventions
BIIB094, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Farmington Hills, Michigan • Cleveland, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 31, 2026, 3:56 AM EDT
Active, not recruiting Not applicable Interventional

The REST Study for CGM Use in Older Adults With Insulin-treated Diabetes

NCT05337826
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Continuous Glucose Monitor
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
65 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 2 Interventional

Growth Hormone to Increase Immune Function in People With HIV

NCT00071240
View directory record Official record
Conditions
HIV Infections
Interventions
Somatropin (recombinant human growth hormone)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2009 · Synced Oct 31, 2026, 3:56 AM EDT
Terminated Phase 3 Interventional

Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

NCT04857840
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Firibastat (QGC001) Period 1
Drug
Lead sponsor
Quantum Genomics SA
Industry
Eligibility
18 Years to 99 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

7 Tesla MRI Study in Patients With Statin Related Muscle Complaints

NCT04575090
View directory record Official record
Conditions
Statin-related Muscle Pain, Muscle Aches, Muscle Weakness, Muscle Cramp, Muscle Stiffness
Interventions
Simvastatin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 31, 2026, 3:56 AM EDT
Recruiting Phase 1 Interventional

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

NCT05798897
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Hodgkin Lymphoma, Adult, Hodgkin's Lymphoma, Relapsed, Adult
Interventions
MT-601
Drug
Lead sponsor
Marker Therapeutics, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Duarte, California • Aurora, Colorado • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Recruiting Phase 2 Interventional

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

NCT07359820
View directory record Official record
Conditions
FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Interventions
Lirafugratinib
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

NCT02489448
View directory record Official record
Conditions
Breast Neoplasms
Interventions
MEDI4736
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 31, 2026, 3:56 AM EDT
Recruiting Phase 4 Interventional

Tirbanibulin for Pediatric Warts

NCT06791525
View directory record Official record
Conditions
Warts Hand
Interventions
Tirbanibulin ointment 1%
Drug
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
8 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

COPE/Healthy Lifestyles for Teens: A School-Based RCT

NCT01704768
View directory record Official record
Conditions
Healthy Lifestyle Behaviors, Depressive/Anxiety Symptoms
Interventions
COPE/Healthy Lifestyles TEEN Program., Healthy Teens Attention Control Program
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
14 Years to 16 Years
Enrollment
1,219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer

NCT00201760
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Trastuzumab, Cisplatin
Drug
Lead sponsor
Kari Kendra
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 2 Interventional Results available

Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer

NCT00232479
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, docetaxel and carboplatin in dose dense regimen
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 31, 2026, 3:56 AM EDT
Active, not recruiting Phase 2 Interventional

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

NCT02452008
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, LY2157299
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

NCT04113668
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986165, diflunisal
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Not applicable Interventional

Accountable Care Organizations/ Public Health Collaborative

NCT02133391
View directory record Official record
Conditions
Immunization Reminder System
Interventions
Centralized Reminder/Recall (R/R), Practice-based Reminder/Recall
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Months and older
Enrollment
78,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 31, 2026, 3:56 AM EDT
Active, not recruiting Not applicable Interventional

PoNS® Therapy for Gait and Balance Deficits in Chronic Stroke Survivors: A Single-Arm Study

NCT06336720
View directory record Official record
Conditions
Chronic Stroke Survivors
Interventions
Portable Neuromodulation Stimulator (PoNS)
Device
Lead sponsor
Helius Medical Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Jacksonville, Florida • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin

NCT05541471
View directory record Official record
Conditions
Pain
Interventions
VX-548, Midazolam, Digoxin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 31, 2026, 3:56 AM EDT
Active, not recruiting No phase listed Observational

Feasibility and Reliability of the Melbourne Assessment-2 (MA-2) for Telehealth

NCT06810063
View directory record Official record
Conditions
Cerebral Palsy, Hemiplegic Cerebral Palsy
Interventions
Assessment only, no intervention
Other
Lead sponsor
Ohio State University
Other
Eligibility
2 Years to 10 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Dissonance-Based Obesity Intervention

NCT04068493
View directory record Official record
Conditions
Obesity
Interventions
Enhanced Project Health
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 25 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 31, 2026, 3:56 AM EDT
Not listed Not applicable Interventional

e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions

NCT02087293
View directory record Official record
Conditions
Diabetes, Depression, Insomnia, Hypertension
Interventions
Intervention arm - automated call and phone-based pharmacist counseling
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
38,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 31, 2026, 3:56 AM EDT
Enrolling by invitation Not applicable Interventional

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder

NCT06374264
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
MR-C-014
Device
Lead sponsor
MedRhythms, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Recruiting Phase 3 Interventional

Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

NCT07473843
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
Zodasiran
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 3:56 AM EDT
Recruiting No phase listed Observational

A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

NCT06192576
View directory record Official record
Conditions
Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency
Interventions
Olipudase alfa
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Up to 2 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Cincinnati, Ohio • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 31, 2026, 3:56 AM EDT